Who is sponsoring NCT01871454?

NCT01871454 is sponsored by University of Louisville.

What drugs are being tested in NCT01871454?

Interventions in NCT01871454: stereotactic ablative radiotherapy (SABR), Pentoxifylline.

What condition does NCT01871454 study?

NCT01871454 studies Non-small Cell Lung Cancers.

Is NCT01871454 still recruiting?

NCT01871454 is currently status unknown. Last updated 6 February 2024.

Last reviewed 2024-02-06 · How we verify

NCT01871454

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Effect of Pentoxifylline and Vitamin E in Preventing Radiation-induced Toxicity in the Treatment of Recurrent or New Primary NSCLC Using Stereotactic Ablative Radiotherapy in Patients Previously Treated With Thoracic Radiation

Status unknown Phase 2 Last updated 6 February 2024

What this trial tests

Phase 2 trial testing stereotactic ablative radiotherapy (SABR) in Non-small Cell Lung Cancers in 59 participants. Status unknown.

Timeline

1 October 2013

Primary endpoint
1 December 2025

1 December 2025

Quick facts

Lead sponsor	University of Louisville
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	59
Start date	1 October 2013
Primary completion	1 December 2025
Estimated completion	1 December 2025
Sites	1 location across United States

Drugs / interventions tested

stereotactic ablative radiotherapy (SABR)
Pentoxifylline — full drug profile →

Conditions studied

Non-small Cell Lung Cancers — all drugs for Non-small Cell Lung Cancers →

Sponsor

University of Louisville

Who can join

18 and older, any sex, with Non-small Cell Lung Cancers. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

primary endpoint is to estimate overall treatment-related toxicity
Time frame: 36 months-end of trial

Sponsor's own description

The objective of this prospective phase II protocol is to assess the toxicity and efficacy of pentoxifylline and SABR in the re-treatment of recurrent or new lung cancers

Publications & conference data

7 peer-reviewed publications reference this trial (live from Europe PMC):

Ferroptosis in cancer: From molecular mechanisms to therapeutic strategies.
Zhou Q, Meng Y, Li D, Yao L, et al · · 2024 · cited 439× · PMID 38453898 · DOI 10.1038/s41392-024-01769-5
Metabolic Regulation of Redox Balance in Cancer.
Purohit V, Simeone DM, Lyssiotis CA. · · 2019 · cited 79× · PMID 31288436 · DOI 10.3390/cancers11070955
Oxidative Stress and Age-Related Tumors.
Di Carlo E, Sorrentino C. · · 2024 · cited 33× · PMID 39334768 · DOI 10.3390/antiox13091109
Pros and Cons of Pharmacological Manipulation of cGMP-PDEs in the Prevention and Treatment of Breast Cancer.
Di Iorio P, Ronci M, Giuliani P, Caciagli F, et al · · 2021 · cited 13× · PMID 35008687 · DOI 10.3390/ijms23010262
Targeting Mitochondrial Metabolism to Reverse Radioresistance: An Alternative to Glucose Metabolism.
Bian C, Zheng Z, Su J, Wang H, et al · · 2022 · cited 11× · PMID 36358574 · DOI 10.3390/antiox11112202
Utilization of Vitamin E Analogs to Protect Normal Tissues While Enhancing Antitumor Effects.
Aykin-Burns N, Pathak R, Boerma M, Kim T, et al · · 2019 · cited 11× · PMID 30573184 · DOI 10.1016/j.semradonc.2018.10.008
Ionizing radiation: molecular mechanisms, biological effects, and therapeutic targets.
Wei W, Ren Y, Lan J, Yi J, et al · · 2026 · PMID 41507636 · DOI 10.1186/s43556-025-00358-4

Verify or expand the search:

Other trials of stereotactic ablative radiotherapy (SABR)

Trials testing the same drug.

NCT05084391 — Phase I/II Randomized Study of Stereotactic Ablative Radiotherapy (SABR) Versus Standard of Care for Refractory Structur · Phase 1, PHASE2 · withdrawn
NCT04037358 — RAdium-223 and SABR Versus SABR for Oligometastatic Prostate Cancers · Phase 2 · completed

Other University of Louisville trials

Trials by the same sponsor.

NCT07219888 — Comparison of Suzetrigine and Oxycodone for Postoperative Pain After Primary Total Knee Arthroplasty · Phase 4 · not yet recruiting
NCT07044726 — Betadine vs Sterile Water for Periurethral Preparation · Phase 4 · not yet recruiting
NCT06489106 — Noninvasive Spinal Stimulation to Restore Hand Function in Children With Spinal Cord Injury · NA · enrolling by invitation
NCT06883513 — Osteopathic Manipulative Therapy Effects on Post-Acute Sequelae of COVID-19 (PASC) or Long COVID · NA · recruiting
NCT05920720 — Self-Guided Personalized Treatment for Women · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT01871454 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Louisville
Last refreshed: 6 February 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT01871454.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing